Abstract
Atherosclerosis (AS) is the leading cause of global mortality and morbidity. Despite the elevated expression of sodium-hydrogen exchanger 1 (NHE1) and olfactory receptor 2 (Olfr2) in plaque macrophages, their interactions within the AS context remain poorly understood. In this study, ApoE(-/-) mice and RAW264.7 macrophages were employed to examine the impact of intraperitoneal octanal injection on atherosclerosis and NHE1 expression in vivo. In vitro analyses were conducted to assess NHE1 expression, activity, and inflammatory responses subsequent to treatment with octanal and an NHE1 inhibitor. Furthermore, the underlying mechanisms were investigated through RNA interference and calcium ion (Ca2+) chelation. In vivo, octanal aggravated AS by upregulating NHE1 within plaques, while NHE1 deficiency resulted in reduced plaque formation and inflammation. In vitro, octanal increased NHE1 expression and activity in a dose- and time-dependent manner in RAW264.7 cells, facilitating foam cell formation and inflammatory responses. NHE1 inhibitors effectively attenuated these effects. Mechanistically, RNA interference targeting Olfr2 or calcium chelation reduced octanal-induced NHE1 upregulation and associated inflammatory responses. These findings highlight NHE1 as a key downstream effector in the Octanal/Olfr2 signaling pathway, suggesting that targeting NHE1 may present a promising therapeutic approach for AS.